Details

Autor(en) / Beteiligte

• Baya, Bocar
• Achenbach, Chad J.
• Kone, Bourahima
• Toloba, Yacouba
• Dabitao, Djeneba K.
• Diarra, Bassirou
• Goita, Drissa
• Diabaté, Seydou
• Maiga, Mamoudou
• Soumare, Dianguina
• Ouattara, Khadidia
• Kanoute, Tenin
• Berthe, Gaoussou
• Kamia, Youssouf M.
• Sarro, Yeya dit Sadio
• Sanogo, Moumine
• Togo, Antieme C.G.
• Dembele, Bindongo P.P.
• Coulibaly, Nadie
• Kone, Amadou
• Akanbi, Maxwell
• Belson, Michael
• Dao, Sounkalo
• Orsega, Susan
• Siddiqui, Sophia
• Doumbia, Seydou
• Murphy, Robert L.
• Diallo, Souleymane

Titel

Clinical risk factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali

Ist Teil von

• International journal of infectious diseases, 2019-04, Vol.81, p.149-155

Ort / Verlag

Canada: Elsevier Ltd

Erscheinungsjahr

2019

Quelle

MEDLINE

Beschreibungen/Notizen

• •MDR-TB was associated with younger age in Mali.•HIV was not a risk factor for MDR-TB.•MDR-TB did alter the patient’s physical condition compared to susceptible TB.•Tobacco consumption did not increase the risk of developing MDR-TB. MDR-TB is a major threat to global TB control. In 2015, 580,000 were treated for MDR-TB worldwide. The worldwide roll-out of GeneXpert MTB/RIF® has improved diagnosis of MDR-TB; however, in many countries laboratories are unable to assess drug resistance and clinical predictors of MDR-TB could help target suspected patients. In this study, we aimed to determine the clinical factors associated with MDR-TB in Bamako, Mali. We performed a cross-sectional study of 214 patients with presumed MDR-TB admitted to University of Bamako Teaching Hospital, Point-G between 2007 and 2016. We calculated crude and adjusted odds ratios for MDR-TB disease diagnosis using SPSS. We found that age ≤40years (OR=2.56. 95% CI: 1.44–4.55), two courses of prior TB treatment (OR=3.25, 95% CI: 1.44–7.30), TB treatment failure (OR=3.82, 95% CI 1.82–7.79), sputum microscopy with 3+ bacilli load (OR=1.98, 95% CI: 1.13–3.48) and a history of contact with a TB patient (OR=2.48, 95% CI: 1.11–5.50) were significantly associated with confirmation of MDR-TB disease. HIV was not a risk factor for MDR-TB (aOR=0.88, 95% CI: 0.34–1.94). We identified several risk factors that could be used to identify MDR-TB suspects and prioritize them for laboratory confirmation. Prospective studies are needed to understand factors associated with TB incidence and clinical outcomes of TB treatment and disease.